CWM
BMRN icon

CIBC World Markets’s BioMarin Pharmaceuticals BMRN Stock Holding History

CIBC World Markets’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$439K Sell
7,985
-687
-8% -$40.5K ﹤0.01% 932
2025
Q1 		$613K Buy
8,672
+57
+0.7% +$3.83K ﹤0.01% 905
2024
Q4 		$566K Sell
8,615
-2,450
-22% -$164K ﹤0.01% 700
2024
Q3 		$778K Buy
11,065
+832
+8% +$69.5K 0.01% 639
2024
Q2 		$842K Sell
10,233
-11,952
-54% -$995K 0.01% 608
2024
Q1 		$1.94M Sell
22,185
-248,057
-92% -$22.2M 0.01% 513
2023
Q4 		$26.1M Buy
+270,242
New +$23.9M 0.14% 114
2023
Q2 		– Sell
-34,000
Closed -$3.31M – 601
2023
Q1 		$3.31M Hold
34,000
– – 0.05% 253
2022
Q4 		$3.52M Hold
34,000
– – 0.02% 390
2022
Q3 		$2.88M Buy
+34,000
New +$3.03M 0.04% 224
2022
Q1 		– Sell
-30,000
Closed -$2.65M – 629
2021
Q4 		$2.65M Buy
+30,000
New +$2.48M 0.01% 358
2020
Q4 		– Sell
-10,091
Closed -$768K – 634
2020
Q3 		$768K Sell
10,091
-1,612
-14% -$163K 0.01% 536
2020
Q2 		$1.44M Sell
11,703
-3,144
-21% -$312K 0.02% 456
2020
Q1 		$1.25M Buy
14,847
+191
+1% +$16.5K 0.02% 415
2019
Q4 		$1.24M Buy
14,656
+8,263
+129% +$624K 0.01% 668
2019
Q3 		$431K Buy
+6,393
New +$492K ﹤0.01% 653
2018
Q4 		– Sell
-4,288
Closed -$416K – 607
2018
Q3 		$416K Buy
+4,288
New +$428K ﹤0.01% 629
2018
Q1 		– Sell
-13,034
Closed -$1.16M – 657
2017
Q4 		$1.16M Sell
13,034
-20
-0.2% -$1.74K 0.01% 611
2017
Q3 		$1.22M Buy
13,054
+104
+0.8% +$9.19K 0.01% 552
2017
Q2 		$1.18M Buy
+12,950
New +$1.18M 0.01% 572
2016
Q4 		– Sell
-3,308
Closed -$306K – 591
2016
Q3 		$306K Sell
3,308
-7,393
-69% -$696K 0.01% 249
2016
Q2 		$833K Buy
10,701
+1,011
+10% +$85.9K 0.02% 178
2016
Q1 		$799K Sell
9,690
-3,681
-28% -$299K 0.02% 181
2015
Q4 		$1.4M Buy
13,371
+2,224
+20% +$232K 0.03% 191
2015
Q3 		$1.17M Buy
+11,147
New +$1.49M 0.03% 192

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

CIBC World Markets's BMRN Position: Q2 2025 in Review

CIBC World Markets reduced its BioMarin Pharmaceuticals (BMRN) stake by 7.9% in Q2 2025, selling an estimated $40.5K and leaving 7,985 shares worth $439K. The position accounts for ﹤0.01% of the portfolio, ranked #932.

CIBC World Markets first reported a position in BMRN in Q3 2015 and has held it in 25 quarters since. The position peaked at $26.1M in Q4 2023. 582 funds tracked by Wall St. Rank hold BMRN as of Q2 2025.

  • CIBC World Markets held 7,985 shares of BioMarin Pharmaceuticals worth $439K as of Q2 2025.
  • CIBC World Markets sold 687 BioMarin Pharmaceuticals shares in Q2 2025, an estimated $40.5K.
  • BioMarin Pharmaceuticals made up ﹤0.01% of CIBC World Markets's portfolio in Q2 2025, its #932 holding.
  • CIBC World Markets first reported a position in BioMarin Pharmaceuticals in Q3 2015 and has held it in 25 quarters since.
  • CIBC World Markets's BioMarin Pharmaceuticals position peaked at $26.1M in Q4 2023.
  • 582 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2025.

Based on CIBC World Markets's 13F filing for Q2 2025, filed 14 Aug 2025.